Influenza hemagglutinin proteins and methods of use thereof

Abstract

In some embodiments the present invention provides influenza hemagglutinin (“HA”) polypeptides, proteins, and protein complexes that comprise a stalk domain that is engineered to facilitate maintenance of its native trimeric conformation, even if the head domain of the HA protein is removed or disrupted. In some embodiments, the present invention provides compositions comprising such polypeptides, proteins, and protein complexes, and methods of use of such proteins and compositions, for example as vaccine immunogens.

1 . An influenza hemagglutinin (HA) polypeptide, protein or protein complex comprising an amino acid sequence having at least 65% sequence identity to amino acid residues 229 to 519 of SEQ ID NO: 1, wherein the amino acid sequence comprises a point mutation to tyrosine at one or more of amino acid positions 403, 406, 411, 422, 429, 432, 433, and 435, or an amino acid residue corresponding thereto. 
     
     
         2 . An influenza hemagglutinin (HA) polypeptide, protein or protein complex according to  claim 1 , wherein the amino acid sequence comprises point mutations to tyrosine at two or more of amino acid positions 403, 406, 411, 422, 429, 432, 433, and 435, or amino acid residues corresponding thereto. 
     
     
         3 . An influenza hemagglutinin (HA) polypeptide that consists essentially of an amino acid sequence having at least 65% sequence identity to amino acid residues 229 to 519 of SEQ ID NO: 1, wherein the amino acid sequence comprises a point mutation to tyrosine at one or more of amino acid positions 403, 406, 411, 422, 429, 432, 433, and 435, or an amino acid residue corresponding thereto. 
     
     
         4 . An influenza HA polypeptide, protein or protein complex according to  claim 1 , wherein the polypeptide, protein or protein complex is folded into a trimeric stalk conformation and comprises at least one di-tyrosine cross-link, wherein one or both tyrosines of the at least one di-tyrosine cross-link originate from a point mutation to tyrosine. 
     
     
         5 . An influenza HA polypeptide according to  claim 3 , wherein the polypeptide is comprised with an influenza HA protein complex that is folded into a trimeric stalk conformation, and wherein the influenza HA protein complex comprises at least one di-tyrosine cross-link, wherein one or both tyrosines of the at least one di-tyrosine cross-link originates from a point mutation to tyrosine. 
     
     
         6 . An influenza HA polypeptide, protein or protein complex according to  claim 4 , wherein the cross-links are located between one or more paired tyrosine residues, wherein the paired tyrosine residues are selected from the group consisting of residues 403 and 433; 411 and 422, 403 and 429, 403 and 432, 433 and 435, and 406 and 433. 
     
     
         7 . An influenza HA protein complex according to  claim 5 , wherein the cross-links are located between one or more paired tyrosine residues, wherein the paired tyrosine residues are selected from the group consisting of residues 403 and 433; 411 and 422, 403 and 429, 403 and 432, 433 and 435, and 406 and 433. 
     
     
         8 . An influenza HA polypeptide, protein or protein complex according to  claim 1 , wherein the influenza HA polypeptide, protein or protein complex has the amino acid sequence of SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 86, 87, 88, 89, 90. 91, 92, 93, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, or 117, or an amino acid sequence having 65% or greater sequence identity to any of such sequences. 
     
     
         9 . An influenza HA polypeptide, protein or protein complex according to  claim 1 , wherein the polypeptide, protein or protein complex is capable of binding to an HA-stalk-specific antibody. 
     
     
         10 . An influenza HA polypeptide, protein or protein complex according to  claim 9 , wherein the polypeptide, protein or protein complex is capable of binding to antibody C179. 
     
     
         11 . An influenza HA polypeptide, protein or protein complex according to  claim 1 , wherein the polypeptide, protein or protein complex is capable of folding into a trimeric stalk conformation. 
     
     
         12 . An influenza HA polypeptide, protein or protein complex according to  claim 1 , wherein the polypeptide, protein or protein complex further comprises a trimerization domain. 
     
     
         13 . An influenza HA polypeptide, protein or protein complex according to  claim 12 , wherein the trimerization domain is a foldon domain. 
     
     
         14 . A nucleic acid molecule encoding an influenza HA polypeptide, protein or protein complex according to  claim 1 . 
     
     
         15 . A composition comprising an influenza HA polypeptide, protein or protein complex according to  claim 1 . 
     
     
         16 . The composition of  claim 16 , wherein the composition is a vaccine composition. 
     
     
         17 . The composition of  claim 17 , wherein the composition further comprises an adjuvant, a carrier, an immunostimulatory agent, or any combination thereof. 
     
     
         18 . A composition comprising an influenza HA polypeptide according to  claim 2 . 
     
     
         19 . A composition comprising an influenza HA polypeptide according to  claim 2  and an influenza HA polypeptide consisting essentially of an amino sequence having at least 65% sequence identity to SEQ ID NO: 94 or SEQ ID NO: 95.